IRVINE, Calif., Oct. 2, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the national availability of JUVÉDERM ® VOLUMA ® XC for temple hollowing. Following its U.S.

At 3 months, findings showed 80.4% of patients treated with Juvéderm Voluma XC achieved at least a 1-point improvement in moderate to severe temple hollowing. The Food and Drug Administration (FDA) ...

Dermatologists and plastic surgeons have a new, nonsurgical weapon to add to their anti-aging arsenal. Juvéderm Voluma XC was approved by the U.S. Food and Drug Administration in December as the first ...

IRVINE, Calif., March 5, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUMA® XC for injection in the ...

NEWPORT BEACH, CA--(Marketwired - Sep 22, 2015) - Dr. Nancy Silverberg, a dermatologist in Newport Beach, believes that looking younger can help patients feel younger, which can improve their overall ...

IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE:AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLUMA™ XC, the ...

Please provide your email address to receive an email when new articles are posted on . “Because there are no permanent adverse reactions or deforming reactions, I think the safety is assured,” Karen ...

Patients treated with Juvéderm Voluma XC to correct infraorbital hollows reported high satisfaction rates and experienced low rates of adverse events, according to a study. A retrospective ...

FDA Advisory Committee Unanimously Recommends JUVÉDERM VOLUMA™ XC as a Safe and Effective Treatment Option for Cheek Augmentation to Correct Age-Related Volume Deficit in the Mid-Face "Today's ...

"The number one facial concern patients have is the eye area,12 so it is essential to consider treating the temples as part of a comprehensive treatment plan. With the approval and training-led launch ...